Clinical Trial Update: A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain [Phase 3]

View source ↗

Summary

A Phase 3 randomized, placebo-controlled trial evaluating OXN PR for pain in Parkinson's disease with severe pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• OXN PR (Oxycodone/naloxone prolonged-release)

Snippet

Sponsor: Mundipharma Research GmbH & Co KG | Conditions: Parkinson's Disease With Severe Pain | Phase 3 | Status: COMPLETED